MARK2P11

Across TCGA pan-cancer cohorts, MARK2P11 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of MARK2P11’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where MARK2P11 RNA is repressed in tumor relative to normal tissue. In most cancer types MARK2P11 is over-expressed in tumor, although a few such as BRCA and COAD show the opposite, repressed pattern.

BRCA, LIHC, and COAD are the cancer types where MARK2P11 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MARK2P11 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	All	All	−0.005	.032	3	view →
LIHC	All	All	+0.005	.038	2	view →
COAD	All	All	−0.009	.049	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

MARK2P11–BRCA

Open the BRCA breakdown →